Recent advances in understanding pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) is an intractable cancer and a leading cause of cancer deaths worldwide. Over 90% of patients die within 1 year of diagnosis. Deaths from PDAC are increasing and it remains a cancer of substantial unmet need. A number of factors contribute to its poor prognosis: namely, late presentation, early metastases and limited systemic therapy options because of chemoresistance. A variety of research approaches underway are aimed at improving patient survival. Here, we review high-risk groups and efforts for early detection. We examine recent developments in the understanding of complex molecular and metabolic alterations which accompany PDAC. We explore artificial intelligence and biological targets for therapy and examine the role of tumour stroma and the immune microenvironment. We also review recent developments with respect to the PDAC microbiome. It is hoped that current research efforts will translate into earlier diagnosis, improvements in treatment and better outcomes for patients

The XMM Cluster Survey: the halo occupation number of BOSS galaxies in X-ray clusters

We present a direct measurement of the mean halo occupation distribution (HOD) of galaxies taken from the eleventh data release (DR11) of the Sloan Digital Sky Survey-III Baryon Oscillation Spectroscopic Survey (BOSS). The HOD of BOSS low-redshift (LOWZ: $0.2 < z < 0.4$) and Constant-Mass (CMASS: $0.43 <z <0.7$) galaxies is inferred via their association with the dark-matter halos of 174 X-ray-selected galaxy clusters drawn from the XMM Cluster Survey (XCS). Halo masses are determined for each galaxy cluster based on X-ray temperature measurements, and range between ${\rm log_{10}} (M_{180}/M_{\odot}) = 13-15$. Our directly measured HODs are consistent with the HOD-model fits inferred via the galaxy-clustering analyses of Parejko et al. for the BOSS LOWZ sample and White et al. for the BOSS CMASS sample. Under the simplifying assumption that the other parameters that describe the HOD hold the values measured by these authors, we have determined a best-fit alpha-index of 0.91$\pm$0.08 and $1.27^{+0.03}_{-0.04}$ for the CMASS and LOWZ HOD, respectively. These alpha-index values are consistent with those measured by White et al. and Parejko et al. In summary, our study provides independent support for the HOD models assumed during the development of the BOSS mock-galaxy catalogues that have subsequently been used to derive BOSS cosmological constraints.Comment: Accepted for publication in MNRAS; 16 pages, 9 figures, 6 tables (1 electronic

Selective Hepatic Vascular Exclusion versus Pringle Maneuver in Major Hepatectomy: A Systematic Review and Meta-Analysis.

ObjectivesMortality and morbidity following hepatic resection is significantly affected by major intra-operative blood loss. This systematic review and meta-analysis evaluates whether selective hepatic vascular exclusion (SHVE) compared to a Pringle maneuver in hepatic resection reduces rates of morbidity and mortality.MethodsA systematic review and meta-analysis were conducted according to the PRISMA guidelines by screening EMBASE, MEDLINE/PubMed, CENTRAL and SCOPUS for comparative studies meeting the inclusion criteria. Pooled odds ratios or mean differences were calculated for outcomes using either fixed- or random-effects models.ResultsSix studies were identified: three randomised controlled trials and three observational studies reporting a total of 2,238 patients. Data synthesis showed significantly decreased rates of mortality, overall complications, blood loss, transfusion requirements, air embolism, liver failure and multi-organ failure in the SHVE group. Rates of hepatic vein rupture, post-operative hemorrhage, operative and warm ischemia time, length of stay in hospital and intensive care unit were not statistically significant between the two groups.ConclusionPerforming SHVE in major hepatectomy may result in reduced rates of morbidity and mortality when compared to a Pringle maneuver. The results of this meta-analysis are based on studies where tumors were adjacent to major vessels. Further RCTs are required to validate these results.Clinical trial registrationPROSPERO (CRD42020212372) https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=212372